<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01314898</url>
  </required_header>
  <id_info>
    <org_study_id>B0171007</org_study_id>
    <secondary_id>B0171007</secondary_id>
    <nct_id>NCT01314898</nct_id>
  </id_info>
  <brief_title>A Single Dose Study Of Antimineralocorticoid Activity Of PF-03882845 In Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Double-Blind (Sponsor-Open), Placebo- And Active-Controlled, Single Dose, Crossover Study To Assess Antimineralocorticoid Activity Of Oral Pf-03882845 In Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      24-hr urinary sodium/potassium ratio will be a sensitive biomarker of antimineralocorticoid
      activity. The dose-response relationship of the antimineralocorticoid activity of PF-03882845
      can be established following single oral doses.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Twenty-four hour urinary Na/K ratio (AUC(0-24)).</measure>
    <time_frame>0-24hr postdose per period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve(AUClast) from the time of dosing to the last data point of PF-03882845.</measure>
    <time_frame>0-24 hr post dose per period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum concentration(Tmax) of PF-03882845.</measure>
    <time_frame>0-24 hr post dose per period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) of PF-03882845.</measure>
    <time_frame>0-24 hr post dose per period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability: Physical examinations, adverse event monitoring, clinical safety laboratory assessments, vital sign measurements and 12-lead ECGs.</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3 mg PF-03882845</intervention_name>
    <description>3 mg PF-03882845, single oral dose</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10 mg PF-03882845</intervention_name>
    <description>10 mg PF-03882845, single oral dose</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>30 mg PF-03882845</intervention_name>
    <description>30 mg PF-03882845, single oral dose</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100 mg PF-03882845</intervention_name>
    <description>100 mg PF-03882845, single oral dose</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>100 mg spironolactone, single oral dose</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and/or female healthy volunteers, age 18 to 55 years. Females must be of
             non-childbearing potential.

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs).

          -  Subjects who are willing and able to comply with scheduled visits, treatment plan,
             laboratory tests, diet restrictions and other trial procedures.

        Exclusion Criteria:

          -  Subjects with a supine BP &gt;140 mm Hg systolic or &gt;90 mm Hg diastolic or &lt;100 mm Hg
             systolic or &lt;60 mm Hg diastolic based on the average of the triplicate

          -  Serum potassium &gt;=5.1 mmol/L or &lt;3.5 mmol/L at screening, confirmed by a single repeat
             if deemed necessary.

          -  Estimated GFR &lt;60 mL/min/1.73 m2 using the Cockcroft-Gault formula measurement of the
             individual parameters following at least 5 minutes of rest at Screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B0171007&amp;StudyName=A%20Single%20Dose%20Study%20Of%20Antimineralocorticoid%20Activity%20Of%20PF-03882845%20In%20Healthy%20Volunteers</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2011</study_first_submitted>
  <study_first_submitted_qc>March 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2011</study_first_posted>
  <last_update_submitted>July 5, 2011</last_update_submitted>
  <last_update_submitted_qc>July 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Single dose</keyword>
  <keyword>cross-over</keyword>
  <keyword>active-control</keyword>
  <keyword>placebo control</keyword>
  <keyword>antimineralocorticoid activity</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

